IBIO stock gains 10% on Australia trial approval for IBIO-600

IBIO shares rose nearly 10% after its muscle-preserving drug IBIO-600 received approval from Australia’s Therapeutic Goods Administration to begin Phase 1 human trials. The study, targeting overweight and obese adults, will assess safety and efficacy, boosting investor sentiment and optimism.